Severe bronchospasm and acute respiratory failure associated with inhaled prostacyclin therapy.
Donna SteinbacherBrian P MurrayThomas DevlinShannon S CarsonH James FordPublished in: Pulmonary circulation (2024)
Prostacyclin therapy is a mainstay of the management of pulmonary arterial hypertension (PAH). Inhaled prostacyclins present safe and effective options for the management of PAH that limit systemic side effects. We describe the first reported case of life-threatening bronchospasm and acute respiratory failure associated with inhaled prostacyclin administration.
Keyphrases
- respiratory failure
- pulmonary arterial hypertension
- extracorporeal membrane oxygenation
- pulmonary artery
- mechanical ventilation
- pulmonary hypertension
- cystic fibrosis
- acute respiratory distress syndrome
- intensive care unit
- early onset
- polycyclic aromatic hydrocarbons
- stem cells
- drug induced
- coronary artery
- mesenchymal stem cells
- cell therapy